The cytokine storm of severe influenza and development of immunomodulatory therapy

Cellular and Molecular Immunology

Volumn 13, Issue 1, 2016, Pages 3-10

  Liu, Qiang ^a   Zhou, Yuan Hong ^a   Yang, Zhan Qiu ^b  

^a CHINA THREE GORGES UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

cytokine storm; immunomodulation; immunopathology; influenza; therapy

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; ASCORBIC ACID; BEZAFIBRATE; CELECOXIB; CHEMOKINE; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; GEMFIBROZIL; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1; MESALAZINE; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; ROSIGLITAZONE; SIALIDASE INHIBITOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1 AGONIST; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; ZANAMIVIR; ANTIVIRUS AGENT; ARBIDOL; CYCLOOXYGENASE 2; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOLOGIC FACTOR; INDOLE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLANT MEDICINAL PRODUCT; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

2009 H1N1 INFLUENZA; ADJUVANT THERAPY; ADULT RESPIRATORY DISTRESS SYNDROME; APOPTOSIS; AVIAN INFLUENZA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; CYTOKINE STORM; DISEASE SEVERITY; DRUG MECHANISM; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; INFLAMMATORY CELL; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA A VIRUS (H7N9); LUNG ALVEOLUS MACROPHAGE; PANDEMIC INFLUENZA; PATHOPHYSIOLOGY; PNEUMONIA; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS REPLICATION; VIRUS VIRULENCE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; VIROLOGY;

ADRENAL CORTEX HORMONES; ANTIOXIDANTS; ANTIVIRAL AGENTS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; CYTOKINES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INDOLES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PLANT PREPARATIONS; RECEPTORS, LYSOSPHINGOLIPID;

EID: 84954211517     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2015.74     Document Type: Review

References (71)

1. Influenza (Seasonal) [World Health Organization, October 2014]. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/.
2. Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis 2006; 12: 15-22.
3. Knipe DM, Howley PM. Fields Virology. 6th ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2013.
4. Liu Q, Liu DY, Yang ZQ. Characteristics of human infection with avian influenza viruses and development of new antiviral agents. Acta Pharmacol Sin 2013; 34: 1257-1269.
5. Zhang W, Wan J, Qian K, Liu X, Xiao Z, Sun J et al. Clinical characteristics of human infection with a novel avian-origin influenza A(H10N8) virus. Chin Med J 2014; 127: 3238-3242.
6. Peiris JS, Hui KP, Yen HL. Host response to influenza virus: protection versus immunopathology. Curr Opin Immunol 2010; 22: 475-481.
7. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev 2012; 76: 16-32.
8. Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, Scott F et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 2011; 146: 980-991.
9. La Gruta NL, Kedzierska K, Stambas J, Doherty PC. A question of selfpreservation: immunopathology in influenza virus infection. Immunol Cell Biol 2007; 85: 85-92.
10. Shinya K, Gao Y, Cilloniz C, Suzuki Y, Fujie M, DengG et al. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque. J Virol 2012; 86: 6055-6066.
11. Hussell T, Goulding J. Structured regulation of inflammation during respiratory viral infection. Lancet Infect Dis 2010; 10: 360-366.
12. Peiris JS, Cheung CY, Leung CY, Nicholls JM. Innate immune responses to influenza A H5N1: friend or foe Trends Immunol 2009; 30: 574-584.
13. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007; 449: 819-826.
14. Barton GM. A calculated response: control of inflammation by the innate immune system. J Clin Invest 2008; 118: 413-420.
15. Wurfel MM. Genetic insights into sepsis: what have we learned and how will it help Curr Pharm Des 2008; 14: 1900-1911.
16. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD et al. Avian influenza A (H5N1) infection in humans. N Eng J Med 2005; 353: 1374-1385.
17. Ichiyama T, Isumi H, Ozawa H, Matsubara T, Morishima T, Furukawa S. Cerebrospinal fluid and serum levels of cytokines and soluble tumor necrosis factor receptor in influenza virus-associated encephalopathy. Scand J Infect Dis 2003; 35: 59-61.
18. Muramoto Y, Shoemaker JE, Le MQ, Itoh Y, Tamura D, Sakai-Tagawa Y et al. Disease severity is associated with differential gene expression at the early and late phases of infection in nonhuman primates infected with different H5N1 highly pathogenic avian influenza viruses. J Virol 2014; 88: 8981-8997. English.
19. Cilloniz C, Pantin-Jackwood MJ, Ni C, Goodman AG, Peng X, Proll SC et al. Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection. J Virol 2010; 84: 7613-7624.
20. De Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12: 1203-1207.
21. Dawson TC, Beck MA, Kuziel WA, Henderson F, Maeda N. Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am J Pathol 2000; 156: 1951-1959.
22. Jin SQ, Li YY, Pan RG, Zou XF. Characterizing and controlling the inflammatory network during influenza A virus infection. Sci Rep 2014; 4: 1-14. English.
23. Ramana CV, Cheng GS, Kumar A, Kwon HJ, Enelow RI. Role of alveolar epithelial early growth response-1 (Egr-1) in CD81 T cellmediated lung injury. Mol Immunol 2009; 47: 623-631.
24. Bermejo-Martin JF, Ortizde Lejarazu R, Pumarola T, Rello J, Almansa R, Ramirez P et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care 2009; 13: R201.
25. Brincks EL, Roberts AD, Cookenham T, Sell S, Kohlmeier JE, Blackman MA et al. Antigen-specific memory regulatory CD41Foxp31 T cells control memory responses to influenza virus infection. J Immunol 2013; 190: 3438-3446.
26. Darwish I, Mubareka S, Liles WC. Immunomodulatory therapy for severe influenza. Expert Rev Anti Infect Ther 2011; 9: 807-822.
27. Brun-Buisson C, Richard JC, Mercat A, Thiebaut AC, Brochard L, Group R-SAHNvR. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011; 183: 1200-1206.
28. Gao HN, Lu HZ, Cao B, Du B, Shang H, Gan JH et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368: 2277-2285.
29. Xu T, Qiao J, Zhao L, He G, Li K, Wang J et al. Effect of dexamethasone on acute respiratory distress syndrome induced by the H5N1 virus in mice. Eur Respir J 2009; 33: 852-860.
30. Kudo K, Takasaki J, Manabe T, Uryu H, Yamada R, Kuroda E et al. Systemic corticosteroids and early administration of antiviral agents for pneumonia with acute wheezing due to influenza A(H1N1)pdm09 in Japan. PLoS One 2012; 7: e32280.
31. Budd A, Alleva L, Alsharifi M, Koskinen A, Smythe V, Mullbacher A et al. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother 2007; 51: 2965-2968.
32. Zheng BJ, Chan KW, Lin YP, Zhao GY, Chan C, Zhang HJ et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008; 105: 8091-8096.
33. Yao M, Yao D, Yamaguchi M, Chida J, Yao D, Kido H. Bezafibrate upregulates carnitine palmitoyltransferase II expression and promotes mitochondrial energy crisis dissipation in fibroblasts of patients with influenza-associated encephalopathy. Mol Genet Metab 2011; 104: 265-272.
34. Bassaganya-Riera J, Song R, Roberts PC, Hontecillas R. PPARgamma activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol 2010; 23: 343-352.
35. Alleva LM, Cai C, Clark IA. Using complementary and alternative medicines to target the host response during severe influenza. Evid Based Complement Alternat Med 2010; 7: 501-510.
36. Oldstone MB, Teijaro JR, Walsh KB, Rosen H. Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection. Virology 2013; 435: 92-101.
37. Carey MA, Bradbury JA, Rebolloso YD, Graves JP, Zeldin DC, Germolec DR. Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice. PLoS One 2010; 5: e11610.
38. Yuan S. Drugs to cure avian influenza infection-multiple ways to prevent cell death. Cell Death Dis 2013; 4: e835.
39. Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW et al. N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol 2010; 79: 413-420.
40. Michaelis M, Geiler J, Naczk P, Sithisarn P, Leutz A, Doerr HW et al. Glycyrrhizin exerts antioxidative effects in H5N1 influenza A virusinfected cells and inhibits virus replication and pro-inflammatory gene expression. PLoS One 2011; 6: e19705.
41. Ely JT. Ascorbic acid role in containment of the world avian flu pandemic. Exp Biol Med 2007; 232: 847-851.
42. Palamara AT, Nencioni L, Aquilano K, De Chiara G, Hernandez L, Cozzolino F et al. Inhibition of influenza A virus replication by resveratrol. J Infect Dis 2005; 191: 1719-1729.
43. Michaelis M, Sithisarn P, Cinatl J, Jr. Effects of flavonoid-induced oxidative stress on anti-H5N1 influenza a virus activity exerted by baicalein and biochanin A. BMC Res Notes 2014; 7: 384.
44. Kesic MJ, Simmons SO, Bauer R, Jaspers I. Nrf2 expression modifies influenza A entry and replication in nasal epithelial cells. Free Radic Biol Med 2011; 51: 444-453.
45. Garozzo A, Tempera G, Ungheri D, Timpanaro R, Castro A. N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection. Int J Immunopathol Pharmacol 2007; 20: 349-354.
46. Kurahashi K, Kajikawa O, Sawa T, Ohara M, Gropper MA, Frank DW et al. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest 1999; 104: 743-750.
47. Salomon R, Hoffmann E, Webster RG. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc Natl Acad Sci USA 2007; 104: 12479-12481.
48. Szretter KJ, Gangappa S, Lu X, Smith C, Shieh WJ, Zaki SR et al. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J Virol 2007; 81: 2736-2744.
49. Bayry J, Thirion M, Misra N, Thorenoor N, Delignat S, Lacroix-Desmazes S et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci 2003; 24: S217-S221.
50. Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 2013; 144: 464-473.
51. Chong PY, Chui P, Ling AE, Franks TJ, Tai DY, Leo YS et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med 2004; 128: 195-204.
52. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment Ann Intern Med 2006; 145: 599-609.
53. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013; 99: 417-435.
54. Liu Z, Guo Z, Wang G, Zhang D, He H, Li G et al. Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice. Eur J Pharm Sci 2009; 38: 215-223.
55. Viasus D, Pano-Pardo JR, Cordero E, Campins A, Lopez-Medrano F, Villoslada A et al. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect 2011; 62: 193-199.
56. Nahmod KA, Nahmod VE, Szvalb AD. Potential mechanisms of AT1 receptor blockers on reducing pneumonia-related mortality. Clin Infect Dis 2013; 56: 1193-1194.
57. Mortensen EM, Nakashima B, Cornell J, Copeland LA, Pugh MJ, Anzueto A et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis 2012; 55: 1466-1473.
58. Lin KL, Sweeney S, Kang BD, Ramsburg E, Gunn MD. CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection. J Immunol 2011; 186: 508-515.
59. Moseley CE, Webster RG, Aldridge JR. Peroxisome proliferatoractivated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza Other Respir Viruses 2010; 4: 307-311.
60. Humphreys IR, Walzl G, Edwards L, Rae A, Hill S, Hussell T. A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J Exp Med 2003; 198: 1237-1242.
61. Kedzierski L, Linossi EM, Kolesnik TB, Day EB, Bird NL, Kile BT et al. Suppressor of cytokine signaling 4 (SOCS4) protects against severe cytokine storm and enhances viral clearance during influenza infection. PLoS Pathog 2014; 10: e1004134.
62. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012; 68: 479-503.
63. Blaising J, Polyak SJ, Pecheur EI. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 2014; 107: 84-94.
64. Liu Q, Xiong HR, Lu L, Liu YY, Luo F, Hou W et al. Antiviral and antiinflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection. Acta Pharmacol Sin 2013; 34: 1075-1083.
65. Guidelines for Management of Avian H7N9 Influenza Infection. Available from: http://www.moh.gov.cn/ewebeditor/uploadfile/2013/04/20130410212136993.doc.
66. Guidelines for Management of Pandemic (H1N1) 2009 Influenza. Available from: http://www.moh.gov.cn/mohwsyjbgs/s9990/200910/43111.shtml.
67. Chen X, Wu T, Liu G. Chinese medicinal herbs for influenza: a systematic review. J Altern Complement Med 2006; 12: 171-180.
68. Chen W, Lim CE, Kang HJ, Liu J. Chinese herbal medicines for the treatment of type A H1N1 influenza: a systematic review of randomized controlled trials. PLoS One 2011; 6: e28093.
69. Poon PM, Wong CK, Fung KP, Fong CY, Wong EL, Lau JT et al. Immunomodulatory effects of a traditional Chinese medicine with potential antiviral activity: a self-control study. Am J Chin Med 2006; 34: 13-21.
70. Liu Q, Lu L, Hua M, Xu Y, Xiong H, Hou W et al. Jiawei-Yupingfeng-Tang, a Chinese herbal formula, inhibits respiratory viral infections in vitro and in vivo. J Ethnopharmacol 2013; 150: 521-528.
71. Ling JX, Wei F, Li N, Li JL, Chen LJ, Liu YY et al. Amelioration of influenza virus-induced reactive oxygen species formation by epigallocatechin gallate derived from green tea. Acta Pharmacol Sin 2012; 33: 1533-1541.